Saddle South Gold Discovery Expands to 500 M Down-Dip With Multiple Broad, Strong Intercepts, New High-Grade Trend Identified; Saddle North Reconnaissance Returns First High-Grade Drill Intercept

VANCOUVER, BRITISH COLUMBIA--(Sept. 18, 2017) -GT Gold Corp. ("GT Gold" or the "Company") (TSX VENTURE:GTT). GT Gold is pleased to provide the following report and assays from ongoing drilling at the Saddle gold discovery, located approximately 10 kilometres off highway 37 on the Company's Tatogga property in northwestern British Columbia, Canada:
Saddle South continues to exhibit the key hallmarks of a significant discovery - high grades with the added benefit of broad, underground-style halos of mineralization, strong widths and zone continuity. This includes: 
aggregate estimated true widths of the significant intercepts announced for all Saddle South core holes reported to date averages 11.12 metres per hole with a corresponding average grade of 11.77 g/t Au
Read more: GT Gold Corp ( GTT )

Solar Alliance Signs LOI to Acquire Tennessee Commercial Solar Company

Acquisition includes ~US $18,000,000 commercial project pipeline
VANCOUVER, BC--(July 10, 2017) - Solar Alliance Energy Inc. ('Solar Alliance') or (the 'Company') (TSX VENTURE: SAN)(OTC: SAENF) is pleased to announce it has signed a Letter of Intent ("LOI") with Thompson Machinery Commerce Corporation ("Thompson Machinery") to acquire Aries Solar, LLC ("Aries"), an established Tennessee commercial solar company that is licensed to operate in four Southeast U.S. states. Pursuant to the LOI, Solar Alliance will acquire all of the assets of Aries, including a pipeline of commercial projects with a potential revenue of ~US $18,000,000 (unaudited). The Aries team consists of experienced commercial solar project developers and technical staff that will enhance Solar Alliance's ability to increase commercial project deal flow across the Company's operations in California, the Northeast U.S. and the Southeast U.S. The Company anticipates this acquisition will materially increase revenues and net income at Solar Alliance.
Read more: Solar Alliance Energy ( SAN )

Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award

DURHAM, NC  / June 28, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, reported that its Pelican Therapeutics subsidiary is on track to meet product development milestones and has received the first tranche of its $15.2 million Cancer Prevention and Research Institute of Texas (CPRIT) grant award.
"We have made significant progress in advancing PTX-25, our lead antibody, towards the clinic, having completed key milestones, including epitope mapping, affinity maturation and antibody development studies," said Jeff Wolf, Founder and CEO of Heat. "We are pleased that Pelican has received the first tranche of its CPRIT award, which provides non-dilutive funding to cover costs of IND-enabling studies towards a comprehensive, 70-patient Phase 1 clinical trial combining PTX-25 with other immune-oncology drugs"
Read more: Heat Biologics Inc ( HTBX )

Silvercorp net income $43.7 million, $0.26 per share, for Fiscal 2017

VANCOUVER, May 25, 2017 - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE: SVM) reported its financial and operating results for the fourth quarter and twelve months ended March 31, 2017.  All amounts are expressed in US Dollars.
Net income attributable to equity shareholders of $43.7 million, or $0.26 per share1, up 589% compared to net income attributable to equity shareholders of $6.3 million, or $0.04 per share in the prior year. Adjusted net income2 attributable to equity shareholders of $38.6 million or $0.23 per share, up 509% from the prior year after adjustment to one-time net impairment reversal of $5.1 million;
Read more: Silvercorp Metals ( SVM )

Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody ” in Conjunction with 2017 ASCO Annual Meeting

SHANGHAI, China and CUPERTINO, Calif., May 19, 2017  -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the publication of an abstract exploring the application of B-cell antigen, CD20, for targeted Chimeric Antigen Receptor T cells (CAR-T) therapy. The abstract has been published in conjunction with the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6, 2017. 
Read more: Cellular Biomedicine Group ( CBMG )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker